Fasnall

Research use only, not for human use.

Fasnall is a selective FASN inhibitor that acts through its co-factor binding sites. Fasnall shows potent anti-tumor activity in the MMTV-Neu model of HER2(+) breast cancer, particularly in combination with carboplatin.

Fasnall is a selective FASN inhibitor that acts through its co-factor binding sites. Fasnall shows potent anti-tumor activity in the MMTV-Neu model of HER2(+) breast cancer, particularly in combination with carboplatin.

Cell Proliferation Assay Cell Line:MCF7, MDA-MB-468, BT474 and SKBR3 cells Concentration:50 μM Incubation Time:24 h, 48 h, 72 h, 96 h, 120 h Result:Inhibited the proliferation of aggressive cell lines, but showed lower activity in the non-tumorigenic cell line MCF10A.Apoptosis Analysis Cell Line:MCF7, MDA-MB-468, BT474 and SKBR3 cells Concentration:25 μM, 50 μM , 75 μM, 100 μM Incubation Time:24 h Result:Induced caspase-3 and caspase-7 activation.

Animal Model:Female MMTV-NEU mice bearing HER2+ breast cancer cellsDosage:15 mg/kg Administration:i.p.; twice weekly; 3 weeks Result:Reduced tumor volume, and increased the median survival of the MMTV-Neu mice to 63 days.

——

Metabolic Enzyme/Protease

Fatty Acid Synthase

PFKFB3|PFKFB1|PFKFB2

——

——

929978-58-5

510.67

C26H30N4O3S2

>98% (HPLC)

——

Cc1ccc(cc1)S(O)(=O)=O.Cc1sc2ncnc(NC3CCN(Cc4ccccc4)C3)c2c1C

——

(-20℃)

With Ice Pack

≥ 2 years